Uveal Melanoma (UM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Uveal Melanoma (UM) Market Outlook

Thelansis’s “Uveal Melanoma (UM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uveal Melanoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Uveal Melanoma (UM) Overview

Ocular melanoma, a type of cancer that originates in the pigment-producing cells of the eye or surrounding area, is a relatively uncommon condition. The two subtypes of ocular melanoma are the uveal and conjunctival forms, which display notable differences. The presentation of ocular melanoma can vary depending on its location and may manifest as symptoms such as blurred vision, reduced visual field, flashing lights, redness, discomfort, pain, or a sensation of pressure. Several risk factors for the development of ocular melanoma have been identified, including fair skin, atypical skin moles, light eye color, iris moles, freckles, and exposure to sun or tanning, as well as a genetic correlation at the CLPTM1L locus between uveal and cutaneous melanoma. The primary mechanisms underlying the development of ocular melanoma may involve oxidative damage to pigmented tissues and genetic alterations resulting from adenine-to-cytosine mutations in uveal melanoma or adenine-to-thymine mutations in ciliochoroidal melanoma. Melanomas may also arise from pre-existing benign lesions known as nevi. The size of the melanoma guides the choice of treatment, which may include plaque radiation therapy, particle beam radiotherapy, transpupillary thermotherapy, laser photocoagulation, gamma knife stereotactic radiosurgery, local surgical resection, or enucleation. A definitive diagnosis of ocular melanoma requires a biopsy, as several other conditions may present similarly, including choroidal nevus, iris nevus, retinal pigment epithelium hypertrophy, and various benign or malignant lesions. Approximately half of the patients with ocular melanoma will develop metastatic disease within 10 to 15 years of diagnosis, with a smaller proportion developing metastases later, 20 to 25 years after initial diagnosis. Metastatic disease is universally fatal.

• The incidence of uveal and conjunctival melanoma is estimated to be 5 cases per million and 0.33 cases per million in the USA. Males have a 30% greater incidence of uveal melanoma than females.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: